Editorially independent. Revenue never influences our rankings. · Updated weekly · Last reviewed June 9, 2026
Clinical Reference

GLP-1 Drug Interactions: Insulin, Anesthesia, Pregnancy

Fact-checked by Adam Kennah, M.D. on . See our fact-checking policy.

GLP-1 receptor agonists have a manageable but real interaction profile. The most consequential interactions are with other glycemic medications (hypoglycemia risk), the gastric-emptying effect on absorption of certain oral medications, and considerations for anesthesia and surgery. This page is a clinical reference, not a substitute for prescriber and pharmacist review.

High-consequence interactions

Insulin and sulfonylureas — hypoglycemia risk

GLP-1 receptor agonists do not, on their own, cause hypoglycemia in non-diabetic patients (the insulin secretion they trigger is glucose-dependent). However, when combined with insulin or a sulfonylurea (glipizide, glyburide, glimepiride), hypoglycemia risk rises sharply.

  • At initiation: Most clinicians reduce sulfonylurea dose by 25–50% and reduce mealtime insulin by 10–20%.
  • During titration: Monitor capillary glucose; expect to continue reducing insulin as appetite and intake decrease.
  • Metformin: No dose adjustment required. Metformin does not cause hypoglycemia.
  • SGLT2 inhibitors: Combination is increasingly common (e.g., for CKD or HFpEF benefit). Hypoglycemia risk minimal unless also on insulin or sulfonylurea.
  • DPP-4 inhibitors: Not used in combination with GLP-1 agonists (mechanistic overlap).

Oral medications with narrow therapeutic windows — gastric emptying effect

Delayed gastric emptying can alter the rate and (less commonly) extent of absorption of oral medications. The clinically meaningful examples:

  • Warfarin: Modest INR fluctuations during titration. Check INR more frequently in the first 2 months.
  • Levothyroxine: Absorption can be affected; monitor TSH 8 weeks after starting or significantly dose-changing GLP-1 therapy.
  • Oral contraceptives: No clinically meaningful reduction in efficacy documented for combination oral contraceptives at typical use. For tirzepatide specifically, the label recommends backup contraception for 4 weeks at initiation and 4 weeks after each dose escalation; the rationale is delayed absorption, not contraceptive failure data.
  • Oral antibiotics with narrow windows (e.g., voriconazole): Use clinical judgment; serum levels may be appropriate.
  • Oral immunosuppressants (tacrolimus, cyclosporine): Levels can shift; monitor with the prescriber.

Anesthesia and surgery

This is the highest-acuity interaction. Delayed gastric emptying raises the risk of pulmonary aspiration during induction of anesthesia. Current consensus guidance (American Society of Anesthesiologists, 2023):

  • Hold GLP-1 receptor agonists for at least 1 week before elective procedures requiring sedation or general anesthesia (for weekly agents).
  • For daily agents (liraglutide), hold for the morning of the procedure.
  • If GLP-1 cannot be held (emergent surgery, recent dose), treat the patient as a full-stomach patient: full preoxygenation, rapid sequence induction, consider gastric ultrasound if available.

Tell every anesthesiologist about your GLP-1 use. This is not optional — it changes the airway plan.

Substance use considerations

  • Alcohol: Many patients report markedly reduced desire to drink and reduced tolerance on GLP-1 therapy. This is a reproducible class effect. Caloric and metabolic impact of alcohol does not change, but consumption frequently does.
  • Tobacco: No documented interaction with cessation pharmacotherapy.
  • Recreational substances: Limited data. Discuss with prescriber.

Contraindications and cautions

  • Personal or family history of medullary thyroid carcinoma (MTC): Contraindicated.
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN-2): Contraindicated.
  • Pregnancy: Contraindicated. Stop GLP-1 therapy ≥2 months before any planned conception (semaglutide); ≥1 month for tirzepatide.
  • Severe gastrointestinal disease: Use with caution. Pre-existing gastroparesis is a relative contraindication.
  • History of pancreatitis: Use with caution; weigh benefit individually.
  • Severe hepatic impairment: Limited safety data; use only if benefit clearly outweighs.

Pregnancy and conception planning

This is consequential and frequently mishandled. GLP-1 therapy frequently restores ovulation in patients with prior obesity-related anovulation. The combination of "I started GLP-1 therapy and unexpectedly conceived" is well documented. If a patient on GLP-1 therapy could become pregnant:

  • Use reliable contraception throughout treatment.
  • If planning to conceive: stop semaglutide ≥2 months before attempting; stop tirzepatide ≥1 month before.
  • If conception occurs during GLP-1 use: stop immediately and contact OB.

How to use this page

This is a clinical reference. It is not a substitute for the prescribing clinician's and dispensing pharmacist's review of the patient's complete medication list. Patients should bring an up-to-date medication list (prescription + over-the-counter + supplements) to every telehealth consultation.